Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Rheumatology

The Road Ahead: Long-Term Health and Monitoring

At a Glance

Living with polymyositis requires proactive long-term monitoring for systemic complications, particularly interstitial lung disease, cardiovascular events, and cancer. Regular lung imaging, enhanced screenings, and prioritizing physical strength over lab results are crucial for long-term health.

Living with polymyositis (PM) means shifting your focus from “finding a diagnosis” to “managing a long-term journey.” Because PM is a systemic disease, it can affect more than just your muscles. Long-term survivorship involves a partnership with your medical team to monitor your lungs, heart, and overall well-being [1].

Learning about these potential complications can seem terrifying at first. However, understanding these risks is exactly why we do proactive screening—many of these issues can be effectively managed or prevented if caught early.

Protecting Your Lungs: The ILD Risk

The most critical complication to watch for is Interstitial Lung Disease (ILD), which affects approximately 41% of people with inflammatory myopathies [2]. In ILD, the immune system causes inflammation and scarring (fibrosis) in the lung tissue, making it harder to breathe [3].

  • How it is monitored: Standard chest X-rays are often not detailed enough. You should have a baseline High-Resolution CT (HRCT) scan and Pulmonary Function Tests (PFTs), which measure how much air your lungs can hold and how well they move oxygen into your blood [4][5].
  • The Antibody Connection: Certain Antisynthetase Syndrome antibodies, like anti-Jo-1, anti-PL-7, or anti-PL-12, are linked to a much higher risk of lung involvement and require more frequent check-ups [6][7].

Cardiovascular Health and Blood Clot Risks

Research shows that patients with PM have an approximately 2.37-fold increased risk of cardiovascular events compared to the general population [8].

  • VTE and DVT: You are at a higher risk for Venous Thromboembolism (VTE), which includes Deep Vein Thrombosis (DVT—a clot usually in the leg) and Pulmonary Embolism (PE—a clot that travels to the lungs) [9][10]. This may be due to increased “prothrombotic” properties in the blood of myositis patients [11].
  • Heart Health: PM is also associated with higher rates of heart failure and myocardial infarction (heart attack) [12][13]. Regular screenings for blood pressure, cholesterol, and heart function are essential parts of long-term care.

Malignancy Risk

Patients with idiopathic inflammatory myopathies have a statistically increased risk of developing cancer (malignancy), particularly within the first three to five years after their symptoms begin [14]. While this risk is generally higher in patients with Dermatomyositis than Polymyositis, it is still elevated across the board [14].

Because specific autoantibodies can predict this risk [15], your doctor will likely recommend age-appropriate and enhanced cancer screenings (such as mammograms, colonoscopies, and imaging) as a standard part of your care plan. Staying up-to-date on these screenings is one of the most powerful ways you can protect your long-term health.

The Monitoring Balance: Numbers vs. Strength

A common trap in PM management is focusing solely on Creatine Kinase (CK) levels. While CK is a helpful marker of muscle damage, it does not tell the whole story [16].

  • Clinical Strength: In some cases, CK levels can remain normal or stable even while a patient is experiencing significant functional decline or slow disease progression [17][18].
  • The Gold Standard: Your doctor should use a standardized physical exam, such as the Manual Muscle Testing (MMT-8), to track your actual physical power. If you feel weaker but your “numbers” look good, your clinical experience should take priority in treatment discussions [19][20].

The Psychological Journey

Living with a rare, chronic disease is physically and mentally taxing. The burden of frequent “maintenance” appointments and the fear of a flare-up can impact your quality of life [1].

  • Validation: It is normal to feel overwhelmed.
  • Integrated Care: Many patients find that “integrated” care—which includes physical therapy to maintain mobility and psychological support to manage the emotional toll—leads to the best long-term outcomes [21].

By staying vigilant about your lungs, heart, and cancer screenings, and prioritizing how you feel over just your lab results, you can take an active role in navigating the years ahead.

Common questions in this guide

How often should my lungs be checked if I have polymyositis?
Because interstitial lung disease is a major risk, you should have a baseline High-Resolution CT scan and Pulmonary Function Tests. Your doctor will determine the frequency of follow-ups based on your specific antibody profile, such as anti-Jo-1.
Does polymyositis increase my risk for blood clots?
Yes, patients with polymyositis have a higher risk of developing blood clots like deep vein thrombosis or pulmonary embolism. You should immediately report symptoms such as redness, warmth, or swelling in a single leg to your healthcare team.
Do I need extra cancer screenings with a polymyositis diagnosis?
Yes, there is an increased risk of developing cancer, particularly within the first three to five years after symptoms begin. Your medical team will recommend enhanced, age-appropriate cancer screenings based on your individual risk factors and antibody profile.
Are my creatine kinase (CK) levels the best way to track my disease?
While CK levels help measure muscle damage, they do not tell the whole story. Your doctor should also perform standardized physical exams, like manual muscle testing, because clinical strength can decline even when lab results appear completely normal.
What is the most critical complication of polymyositis to watch out for?
The most critical complication is Interstitial Lung Disease (ILD), which causes inflammation and scarring in the lung tissue. Monitoring for breathing difficulties and undergoing regular pulmonary testing is essential to catch and manage this early.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my antibody profile, how frequently should I have a High-Resolution CT (HRCT) or Pulmonary Function Tests (PFTs)?
  2. 2.Given my increased risk for blood clots (VTE/DVT), what symptoms should I watch for, and do I need any preventative measures?
  3. 3.What specific cancer screenings should I schedule this year to ensure we are proactively monitoring my malignancy risk?
  4. 4.If my CK levels are normal but I feel weaker, how will we adjust my treatment plan?
  5. 5.Can you recommend a mental health professional or support group experienced with chronic, rare autoimmune diseases?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    [Idiopathic inflammatory myopathies. A review].

    Acosta I, Matamala JM, Jara P, et al.

    Revista medica de Chile 2019; (147(3)):342-355 doi:10.4067/S0034-98872019000300342.

    PMID: 31344172
  2. 2

    Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020.

    Sun KY, Fan Y, Wang YX, et al.

    Seminars in arthritis and rheumatism 2021; (51(1)):175-191 doi:10.1016/j.semarthrit.2020.11.009.

    PMID: 33383294
  3. 3

    Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy.

    Bai Z, Shen G, Dong L

    International journal of rheumatic diseases 2021; (24(6)):815-827 doi:10.1111/1756-185X.14128.

    PMID: 34028988
  4. 4

    High-Resolution CT Findings of Myositis-Related Interstitial Lung Disease.

    Egashira R

    Medicina (Kaunas, Lithuania) 2021; (57(7)) doi:10.3390/medicina57070692.

    PMID: 34356972
  5. 5

    Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies.

    Mugii N, Someya F

    Rheumatology international 2018; (38(8)):1443-1448 doi:10.1007/s00296-018-4050-0.

    PMID: 29761224
  6. 6

    Clinical Characteristics and Risk Factors of Polymyositis and Dermatomyositis Combined with Interstitial Lung Disease in Patients Residing in the Northeast Sichuan Province of China.

    Li T, Tang ZY, Zhang QB, et al.

    Current rheumatology reviews 2023; (19(4)):455-462 doi:10.2174/1573397119666230330082452.

    PMID: 37005523
  7. 7

    A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.

    Patel P, Marinock JM, Ajmeri A, Brent LH

    International journal of molecular sciences 2024; (25(8)) doi:10.3390/ijms25084453.

    PMID: 38674039
  8. 8

    Cardiovascular events in adult polymyositis and dermatomyositis: a meta-analysis of observational studies.

    Xiong A, Hu Z, Zhou S, et al.

    Rheumatology (Oxford, England) 2022; (61(7)):2728-2739 doi:10.1093/rheumatology/keab851.

    PMID: 34791063
  9. 9

    Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis.

    Lee YH, Song GG

    Rheumatology international 2017; (37(7)):1165-1173 doi:10.1007/s00296-017-3735-0.

    PMID: 28493173
  10. 10

    Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis.

    Li Y, Wang P, Li L, et al.

    Therapeutics and clinical risk management 2018; (14()):157-165 doi:10.2147/TCRM.S157085.

    PMID: 29416342
  11. 11

    Thrombin generation potential is increased in patients with autoimmune inflammatory myopathies.

    Kuszmiersz P, Siwiec-Koźlik A, Pacholczak-Madej R, et al.

    Advances in medical sciences 2022; (67(2)):346-352 doi:10.1016/j.advms.2022.08.005.

    PMID: 36084366
  12. 12

    Increased long-term risk of heart failure and other adverse cardiac outcomes in dermatomyositis and polymyositis: Insights from a nationwide cohort.

    Yafasova A, Diederichsen LP, Schou M, et al.

    Journal of internal medicine 2021; (290(3)):704-714 doi:10.1111/joim.13309.

    PMID: 34080737
  13. 13

    Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study.

    Rai SK, Choi HK, Sayre EC, Aviña-Zubieta JA

    Rheumatology (Oxford, England) 2016; (55(3)):461-9 doi:10.1093/rheumatology/kev336.

    PMID: 26424835
  14. 14

    Risk of Malignancy in Dermatomyositis and Polymyositis.

    Qiang JK, Kim WB, Baibergenova A, Alhusayen R

    Journal of cutaneous medicine and surgery 2017; (21(2)):131-136 doi:10.1177/1203475416665601.

    PMID: 27534779
  15. 15

    The value of myositis-specific autoantibodies in the diagnosis of idiopathic inflammatory myopathy and tumor risk prediction.

    Shi L, Min R, Wu Y, et al.

    The Journal of international medical research 2025; (53(8)):3000605251362969 doi:10.1177/03000605251362969.

    PMID: 40757783
  16. 16

    Causes of creatine kinase levels greater than 1000 IU/L in patients referred to rheumatology.

    Leverenz D, Zaha O, Crofford LJ, Chung CP

    Clinical rheumatology 2016; (35(6)):1541-7 doi:10.1007/s10067-016-3242-9.

    PMID: 27041384
  17. 17

    The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort.

    Edigin E, Hassan AS, Mathur T, Manadan A

    Cureus 2020; (12(8)):e9873 doi:10.7759/cureus.9873.

    PMID: 32963913
  18. 18

    Idiopathic Inflammatory Myopathy With Normal Creatine Kinase Levels in an Elderly Patient: A Diagnostic Challenge.

    Chilakuluri P, Debnath V, Barakat A, et al.

    Cureus 2025; (17(12)):e100301 doi:10.7759/cureus.100301.

    PMID: 41613726
  19. 19

    The Correlation of Muscle Biopsy Scores with the Clinical Variables in Idiopathic Inflammatory Myopathies.

    Wangkaew S, Suwansirikul S, Aroonrungwichian K, et al.

    The open rheumatology journal 2016; (10()):141-149 doi:10.2174/1874312901610010141.

    PMID: 28144368
  20. 20

    2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

    Aggarwal R, Rider LG, Ruperto N, et al.

    Annals of the rheumatic diseases 2017; (76(5)):792-801 doi:10.1136/annrheumdis-2017-211400.

    PMID: 28385805
  21. 21

    PM10 increases mortality risk in rheumatoid arthritis-associated interstitial lung disease.

    Kim SH, Kim SY, Yoon HY, Song JW

    RMD open 2024; (10(1)) doi:10.1136/rmdopen-2023-003680.

    PMID: 38331470

This page provides information on long-term polymyositis monitoring for educational purposes only. Always consult your rheumatologist and care team for personalized screening, monitoring, and treatment plans.

Get notified when new evidence is published on Polymyositis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.